One study found that about 67% of patients taking Structure Therapeutics’s pill lost over 6% of their weight and about 33% ...

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...

Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and ...

Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.

As we continue to make progress on increasing supply for Wegovy ® (WegovySupply.com) to meet continued demand, Novo Nordisk is equally focused on reinforcing the U.S. Food and Drug Administration (FDA ...

Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...

In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...

(Reuters) – Structure Therapeutics said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations and sending shares ...